Skip to main contentSkip to navigation
Sirius Investors
Guardant Health, Inc.

Guardant Health, Inc.

GH
NASDAQHealthcare

Revenue Analysis - GH

Comprehensive quarterly and annual revenue breakdown by product lines and geographic regions to identify growth drivers and market opportunities.

GH Corporation

Annual

Revenue by Product Line

Latest quarterly revenue breakdown by product segments

Quarterly Product Revenue

Product Revenue Details

Detailed breakdown of revenue by product line

Oncology

0.0% of total revenue

$205.0M

Biopharma & Data

0.0% of total revenue

$53.0M

Screening

0.0% of total revenue

$41.6M

Licensing & Other

0.0% of total revenue

$2.1M

Historical Revenue Data

Quarterly product revenue breakdown over time (Last 5 records)

Date
Biopharma & Data
Licensing & Other
Oncology
Screening
3/31/2026$53.0M$2.1M$205.0M$41.6M
12/31/2025$54.0M$2.2M$189.9M$35.1M
9/30/2025$54.7M$2.0M$184.4M$24.1M
6/30/2025$56.0M$2.6M$158.7M$14.8M
3/31/2025$45.4M$1.9M$150.6M$5.7M

Revenue Trend Analysis

Analysis of major growing and declining segments based on recent revenue data

Product Segments

Growing Segments
Screening+18.4%

Geographic Regions

Stable Segments
UNITED STATES+8.0%
Non-US-3.9%

Earnings Reports

Want to see how GH's earnings relate to revenue? View quarterly earnings results, EPS history, and earnings surprises to understand the company's profitability.

View Earnings Reports